Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Protocol | Alliance A081105 |
---|---|
Cancer Type: | Non-Small Cell Lung |
Fast Facts |
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
A substudy of ALCHEMIST A151216
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG LU006 |
---|---|
Cancer Type: | MALIGNANT PLEURAL MESOTHELIOMA |
PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | ECOG E4512 |
---|---|
Cancer Type: | Non-Small Cell Lung |
Fast Facts |
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A substudy of ALCHEMIST A151216
Protocol | EA5162 |
---|---|
Cancer Type: | Advanced NSCLC |
Fast Facts |
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
Protocol | EA5163 |
---|---|
Cancer Type: | Non-Small Cell Lung Cancer (NSCLC) |
Fast Facts |
A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis
Protocol | EA5181 |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Protocol | NRG LU002 |
---|---|
Cancer Type: | METASTATIC NON-SMALL CELL LUNG CANCER |
Fast Facts |
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Protocol | SWOG S1400F |
---|---|
Cancer Type: | Lung Cancer |
Fast Facts |
A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)
Protocol | SWOG S1900A |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Protocol | SWOG S1900B |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Protocol | NRG LU003 |
---|---|
Cancer Type: | ALK Positive Non Squamous NSCLC |
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol
Protocol | SWOG S1914 |
---|---|
Cancer Type: | Early Stage NSCLC |
Fast Facts |
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Protocol | Alliance A081801 |
---|---|
Cancer Type: | resected NSCLC |
Fast Facts |
Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
Protocol | EA5191 |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG CC003 |
---|---|
Cancer Type: | SCLC |
Fast Facts |
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Protocol | NRG LU005 |
---|---|
Cancer Type: | Limited Stage Small Cell Lung Cancer |
Fast Facts |
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Protocol | SWOG S1827 |
---|---|
Cancer Type: | Small Cell Lung |
Fast Facts |
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Protocol | SWOG S1929 |
---|---|
Cancer Type: | ES-SCLC |
Fast Facts |
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Protocol | NRG LU007 |
---|---|
Cancer Type: | ES-SCLC |
Fast Facts |
RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | ACCRU 2018-01 |
---|---|
Cancer Type: | Untreated Solid Tumors |
Fast Facts |
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1714 |
---|---|
Cancer Type: | Multiple Cancer control |
Fast Facts |
A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A151216 |
---|---|
Cancer Type: | Non-Small Cell Lung |
Fast Facts |
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Sub-Studies to ALCHEMIST: A081105, E4512 and EA5142
Protocol | LUNG MAP |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.